Ranolazine

A true pluripotent cardiovascular drug or jack of all trades, master of none?

Alice Mezincescu, V. J. Karthikeyan, Sunil K. Nadar

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Although the majority of patients with CVD are treated with interventional procedures, a substantial number require medical therapy in terms of both prognosis and symptomatic relief. However, commonly used agents such as β-blockers and calcium channel blockers reduce blood pressure in patients whose resting pressures are often already low. Ranolazine is a promising agent that does not have significant effects on blood pressure or heart rate. Use of this drug has been documented in various cardiovascular conditions, including ischaemic heart disease, heart failure and arrhythmias. This review article aimed to examine current evidence on the use of ranolazine in various cardiovascular conditions in order to determine whether it is a true pluripotent cardiovascular agent or, on the other hand, a “jack of all trades, master of none.”.

Original languageEnglish
Pages (from-to)e13-e23
JournalSultan Qaboos University Medical Journal
Volume18
Issue number1
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Cardiovascular Agents
Cardiovascular Diseases
Blood Pressure
Calcium Channel Blockers
Myocardial Ischemia
Cardiac Arrhythmias
Heart Failure
Heart Rate
Morbidity
Pressure
Mortality
Pharmaceutical Preparations
Ranolazine
Therapeutics

Keywords

  • Cardiovascular agents
  • Cardiovascular diseases
  • Drug therapy
  • Ischemic heart disease
  • Ranolazine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ranolazine : A true pluripotent cardiovascular drug or jack of all trades, master of none? / Mezincescu, Alice; Karthikeyan, V. J.; Nadar, Sunil K.

In: Sultan Qaboos University Medical Journal, Vol. 18, No. 1, 01.02.2018, p. e13-e23.

Research output: Contribution to journalReview article

@article{74d00477a829461a89a2656a91562d20,
title = "Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?",
abstract = "Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Although the majority of patients with CVD are treated with interventional procedures, a substantial number require medical therapy in terms of both prognosis and symptomatic relief. However, commonly used agents such as β-blockers and calcium channel blockers reduce blood pressure in patients whose resting pressures are often already low. Ranolazine is a promising agent that does not have significant effects on blood pressure or heart rate. Use of this drug has been documented in various cardiovascular conditions, including ischaemic heart disease, heart failure and arrhythmias. This review article aimed to examine current evidence on the use of ranolazine in various cardiovascular conditions in order to determine whether it is a true pluripotent cardiovascular agent or, on the other hand, a “jack of all trades, master of none.”.",
keywords = "Cardiovascular agents, Cardiovascular diseases, Drug therapy, Ischemic heart disease, Ranolazine",
author = "Alice Mezincescu and Karthikeyan, {V. J.} and Nadar, {Sunil K.}",
year = "2018",
month = "2",
day = "1",
doi = "10.18295/squmj.2018.18.01.003",
language = "English",
volume = "18",
pages = "e13--e23",
journal = "Sultan Qaboos University Medical Journal",
issn = "2075-051X",
publisher = "Sultan Qaboos University",
number = "1",

}

TY - JOUR

T1 - Ranolazine

T2 - A true pluripotent cardiovascular drug or jack of all trades, master of none?

AU - Mezincescu, Alice

AU - Karthikeyan, V. J.

AU - Nadar, Sunil K.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Although the majority of patients with CVD are treated with interventional procedures, a substantial number require medical therapy in terms of both prognosis and symptomatic relief. However, commonly used agents such as β-blockers and calcium channel blockers reduce blood pressure in patients whose resting pressures are often already low. Ranolazine is a promising agent that does not have significant effects on blood pressure or heart rate. Use of this drug has been documented in various cardiovascular conditions, including ischaemic heart disease, heart failure and arrhythmias. This review article aimed to examine current evidence on the use of ranolazine in various cardiovascular conditions in order to determine whether it is a true pluripotent cardiovascular agent or, on the other hand, a “jack of all trades, master of none.”.

AB - Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Although the majority of patients with CVD are treated with interventional procedures, a substantial number require medical therapy in terms of both prognosis and symptomatic relief. However, commonly used agents such as β-blockers and calcium channel blockers reduce blood pressure in patients whose resting pressures are often already low. Ranolazine is a promising agent that does not have significant effects on blood pressure or heart rate. Use of this drug has been documented in various cardiovascular conditions, including ischaemic heart disease, heart failure and arrhythmias. This review article aimed to examine current evidence on the use of ranolazine in various cardiovascular conditions in order to determine whether it is a true pluripotent cardiovascular agent or, on the other hand, a “jack of all trades, master of none.”.

KW - Cardiovascular agents

KW - Cardiovascular diseases

KW - Drug therapy

KW - Ischemic heart disease

KW - Ranolazine

UR - http://www.scopus.com/inward/record.url?scp=85045004106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045004106&partnerID=8YFLogxK

U2 - 10.18295/squmj.2018.18.01.003

DO - 10.18295/squmj.2018.18.01.003

M3 - Review article

VL - 18

SP - e13-e23

JO - Sultan Qaboos University Medical Journal

JF - Sultan Qaboos University Medical Journal

SN - 2075-051X

IS - 1

ER -